Uncategorized

BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOs

Published

on

BlossomHill Therapeutics will use its $150 million IPO proceeds to power the Phase 1/2 development of a non-small cell lung cancer drug, while Latigo Therapeutics will bring in more than $345 million for its late-stage non-opioid pain pill.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version